The Company
ten23 health® - a CDMO, is located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test tomorrow’s sterile medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health combines the latest scientific findings with our proven and tested world-class industry and regulatory expertise to forge new paths for supporting our clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. Patients, People, Planet
Our Name
The numeric value for the number of molecules in a sample of one mole, is called the Avogadro constant and is 6.022 × 1023. The world is built from small units, and not a homogenous mass.
Our main investor
3i
3i’s Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m and €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare, and business and technology services industries.
For further information, please visit www.3i.com
